Royce & Associates LP Sells 569,815 Shares of Haemonetics Corporation $HAE

Royce & Associates LP lowered its holdings in Haemonetics Corporation (NYSE:HAE) by 44.8% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 701,242 shares of the medical instruments supplier’s stock after selling 569,815 shares during the period. Royce & Associates LP owned about 1.50% of Haemonetics worth $34,179,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. EverSource Wealth Advisors LLC boosted its stake in Haemonetics by 2,640.0% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 411 shares of the medical instruments supplier’s stock valued at $31,000 after purchasing an additional 396 shares during the period. Versant Capital Management Inc boosted its position in shares of Haemonetics by 216.4% in the third quarter. Versant Capital Management Inc now owns 829 shares of the medical instruments supplier’s stock valued at $40,000 after acquiring an additional 567 shares during the period. Byrne Asset Management LLC bought a new stake in shares of Haemonetics in the third quarter valued at about $42,000. Elevation Point Wealth Partners LLC acquired a new position in shares of Haemonetics in the second quarter valued at about $64,000. Finally, Hantz Financial Services Inc. increased its position in Haemonetics by 792.1% during the third quarter. Hantz Financial Services Inc. now owns 1,124 shares of the medical instruments supplier’s stock worth $55,000 after acquiring an additional 998 shares during the period. Institutional investors and hedge funds own 99.67% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on HAE shares. CJS Securities upgraded Haemonetics to a “strong-buy” rating in a research report on Thursday, December 11th. Mizuho dropped their target price on shares of Haemonetics from $90.00 to $80.00 and set an “outperform” rating for the company in a report on Friday, February 6th. Robert W. Baird set a $81.00 price target on shares of Haemonetics in a report on Friday, February 6th. Weiss Ratings reiterated a “hold (c)” rating on shares of Haemonetics in a research report on Monday, December 29th. Finally, Raymond James Financial restated an “outperform” rating and issued a $90.00 target price on shares of Haemonetics in a research report on Friday, November 14th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, Haemonetics presently has an average rating of “Moderate Buy” and an average price target of $84.44.

Haemonetics Price Performance

NYSE HAE opened at $63.28 on Monday. The business’s fifty day moving average price is $70.13 and its 200-day moving average price is $64.19. The stock has a market capitalization of $2.94 billion, a price-to-earnings ratio of 17.43, a PEG ratio of 1.32 and a beta of 0.28. Haemonetics Corporation has a 1-year low of $47.31 and a 1-year high of $87.32. The company has a debt-to-equity ratio of 1.01, a current ratio of 1.75 and a quick ratio of 1.15.

Haemonetics (NYSE:HAE) last posted its quarterly earnings data on Thursday, February 5th. The medical instruments supplier reported $1.31 EPS for the quarter, topping the consensus estimate of $1.27 by $0.04. Haemonetics had a return on equity of 27.32% and a net margin of 13.31%.The firm had revenue of $338.97 million during the quarter, compared to analyst estimates of $331.90 million. During the same period in the prior year, the business posted $1.19 EPS. Haemonetics’s revenue was down 2.7% on a year-over-year basis. Haemonetics has set its FY 2026 guidance at 4.900-5.000 EPS. On average, equities analysts predict that Haemonetics Corporation will post 4.55 earnings per share for the current year.

Haemonetics Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.